Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Xu, Da zhi ^a,b   Geng, Qi rong ^a,b   Tian, Ying ^a   Cai, Mu yan ^a,b   Fang, Xin juan ^b   Zhan, You qing ^a,b   Zhou, Zhi wei ^a,b   Li, Wei ^a,b   Chen, Ying bo ^a,b   Sun, Xiao wei ^a,b   Guan, Yuan xiang ^a,b   Li, Yuan fang ^a,b   Lin, Tong yu ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53; S6 KINASE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MTOR PROTEIN, HUMAN; RAPAMYCIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DOWN REGULATION; DRUG TARGETING; FEMALE; GASTRECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL TIME; UPREGULATION; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; STOMACH TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 77957357004     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-536     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics.2006. CA Cancer J Clin 2006, 56(2):106-30. 10.3322/canjclin.56.2.106, 16514137.
2. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008, 359(5):453-62. 10.1056/NEJMoa0707035, 18669424.
3. Liu TS, Wang Y, Chen SY, Sun YH. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol 2008, 34(11):1208-16.
4. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003, 362(9380):305-15. 10.1016/S0140-6736(03)13975-X, 12892963.
5. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005, 241(1):27-39. 1356843, 15621988.
6. Xu DZ, Geng QR, Long ZJ, Zhan YQ, Li W, Zhou ZW, Chen YB, Sun XW, Chen G, Liu Q. Positive Lymph Node Ratio Is an Independent Prognostic Factor in Gastric Cancer After D2 Resection Regardless of the Examined Number of Lymph Nodes. Ann Surg Oncol 2009, 16(2):319-26. 10.1245/s10434-008-0240-4, 19050970.
7. Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for locally advanced gastric cancer. World J Gastroenterol 2004, 10(18):2727-30.
8. Sutter AP, Zeitz M, Scherübl H. Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. Onkologie 2004, 27(1):17-21. 10.1159/000075600, 15007244.
9. Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, Imperatore V, La Manna G, Pinto M, Ciardiello F, La Mura A, et al. p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. J Surg Oncol 2006, 93(3):241-52. 10.1002/jso.20402, 16482605.
10. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008, 15(1):69-79. 10.1245/s10434-007-9596-0, 17896140.
11. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007, 31(7):1458-68. 10.1007/s00268-007-9016-4, 17516110.
12. García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P, García-Muñiz JL. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003, 10(3):234-41. 10.1245/ASO.2003.05.010, 12679307.
13. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007, 109(4):658-67. 10.1002/cncr.22445, 17211865.
14. Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim CO, Kim SJ, Jeong JS, Kim HJ. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008, 1(8):123.
15. Zhou D, Pan G, Zheng C, Zheng J, Yian L, Teng X. Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues. BMC Cancer 2008, 28(8):353.
16. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004, 10(24):8421-5. 10.1158/1078-0432.CCR-04-0941, 15623621.
17. Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, Paik NS. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 2008, 110(3):477-83. 10.1007/s10549-007-9746-x, 17805960.
18. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007, 13(16):4795-9. 10.1158/1078-0432.CCR-07-0738, 17699857.
19. Faried LS, Faried A, Kanuma T, Sano T, Nakazato T, Tamura T, Kuwano H, Minegishi T. Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol Rep 2006, 16(1):57-63.
20. Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H, Minegishi T. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog 2008, 47(6):446-57. 10.1002/mc.20402, 18058806.
21. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 2007, 120(8):1803-10. 10.1002/ijc.22442, 17230506.
22. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637):449-56. 10.1016/S0140-6736(08)61039-9, 18653228.
23. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004, 10(6):594-601. 10.1038/nm1052, 15156201.
24. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120(6):747-59. 10.1016/j.cell.2004.12.040, 15797377.
25. Ning X, Yang S, Wang R, Zhang R, Guo L, Tie J, Cheng Y, Wang G, Wan S, Fang D. POT1 deficiency alters telomere length and telomere-associated gene expression in human gastric cancer cells. Eur J Cancer Prev 2010, 19(5):345-51. 10.1097/CEJ.0b013e32833b4812, 20517159.
26. Sobin LH, Wittenkind CH. International Union Against Cancer: TNM Classification of Malignant Tumors 2002, New York: John Wiley-Liss, 6.
27. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006, 6(9):729-34. 10.1038/nrc1974, 16915295.
28. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994, 369(6483):756-8. 10.1038/369756a0, 8008069.
29. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006, 124(3):471-84. 10.1016/j.cell.2006.01.016, 16469695.
30. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 2009, 15(5):1821-9. 10.1158/1078-0432.CCR-08-2138, 19223493.
31. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer 2009, 100(5):782-8. 10.1038/sj.bjc.6604915, 2653759, 19223902.
32. Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res 2008, 28(6A):3801-8.
33. Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 2008, 7(9):1377-85.